Pluriomics publishes a new application note for using Pluricyte® Cardiomyocytes in the Axion Maestro MEA system

Leiden, The Netherlands, April 11, 2016 – Pluriomics, a leading expert in human cardiovascular stem cell technology, has published a new application note describing the use of Pluricyte® Cardiomyocytes in the Axion Maestro MEA system. This new application note includes extensive protocols on thawing, plating and culturing Pluricyte® Cardiomyocytes in the Axion Maestro MEA system as well […]

READ MORE read more

Pluriomics strengthens and completes its management team with VP Business Development & Marketing

Leiden, The Netherlands – Pluriomics, a stem cell company commercializing Pluricyte® Cardiomyocytes and assays thereof, announces the appointment of Celine Hechard, PhD as VP Business Development & Marketing. “Pluriomics has made this key appointment to strengthen its management team. The appointment adds a substantial skillset and expertise in further commercialization of our unique products that […]

READ MORE read more

News archive

10th International Meeting on Substrate-Integrated Microelectrode Arrays (MEA 2016)

Date: June 28 – July 1, 2016Location: Reutlingen, Germany Pluriomics will present and exhibit at the 10th International Meeting on Substrate-Integrated Microelectrode Arrays (MEA 2016) in Reutlingen, Germany. Where can you find us? Stop by booth #6 to meet us and hear about our recent developments, new products and applications. We will be happy to discuss the new […]

READ MORE read more

12th European Functional Drug Screening Symposium – FDSS User Meeting

Date: Thursday June 9th, 2016, 8:30 – 20:30h Location: Avinguda Diagonal, 205, 08018 Barcelona, Spain Pluriomics will be presenting at the 12th European Functional Drug Screening Symposium – FDSS User Meeting in Barcelona on June 9th, 2016. Dr. Marijn Vlaming will be giving two inspiring talks entitled: Multiparametric assessment of the effects of cardioactive compounds on human iPSC-derived cardiomyocytes […]

READ MORE read more

Events archive

About us

Pluriomics develops and commercializes fully functional, human iPSC-derived cardiomyocytes and provides high quality services for efficient and reliable safety pharmacology testing and cardiovascular drug efficacy screening.

Pluriomics, a leading expert in human cardiovascular stem cell technology, manufactures fully functional human iPSC derived cardiomyocytes (Pluricyte® Cardiomyocytes) using well-defined, serum-free medium that enhances the maturation and function of the cells. Pluriomics combines Pluricyte® Cardiomyocytes with innovative technologies to develop in-house cell-based assays with the objective to improve drug safety and efficacy screening.

Read more

Pluricyte® Cardiomyocyte Kit

Pluricyte® Cardiomyocyte Kit is developed and manufactured for use in
drug discovery and development. The kit includes both
 Pluricyte® Cardiomyocytes and Pluricyte® Cardiomyocyte Medium (serum-free).

iView product information

Pluriomics' products

Our solutions